News | March 12, 2012

Study Released Comparing MRI Contrast Agents

Study Released Comparing MRI Contrast Agents

March 12, 2012 — A new study shows that the use of gadobenate dimeglumine, the highest relaxivity gadolinium-based contrast agent (GBCA) available for central nervous system (CNS) magnetic resonance imaging (MRI), over a high concentration MRI contrast agent may improve clinicians’ ability to visualize lesions of the brain.

Results of the MERIT Study, the latest in a series of intraindividual studies directly comparing MRI contrast agents within the same test subjects, are published online in the American Journal of Neuroradiology. The findings suggest that the higher relaxivity agent, gadobenate dimeglumine may be linked to greater signal intensity, better contrast enhancement, and better lesion conspicuity in MRI of the brain. The authors also concluded that high concentration does not provide the same benefit as high relaxivity in improving diagnostic performance.

In this large multicenter, randomized, double-blind crossover intraindividual study, researchers compared MultiHance to Gadavist. They concluded that MultiHance provided significantly greater morphologic information, lesion enhancement and contrast enhancement when compared to Gadavist, at equivalent doses for MRI of the brain. They also found no relevant benefit for the more highly concentrated Gadavist in terms of lesion conspicuity, visualization or sensitivity for detection.

The study’s aim was to compare the two agents using a carefully controlled multicenter, double-blind, randomized, intraindividual crossover study design, in which each of the 114 patients received 0.1 mmol/kg doses of both agents in two identical MR imaging examinations. This study is of particular interest because Gadavist differs from other approved GBCAs in that it is formulated at double concentration (twice the concentration of gadolinium is present per unit volume). As of 2011, there have been no studies performed to compare the more highly concentrated Gadavist with the higher relaxivity agent MultiHance for MRI imaging of brain tumors.

The authors stated “two conclusions can be drawn from our findings. Firstly, it is clear that contrast agent concentration in the vial has no effect on imaging performance since injection of the more highly concentrated (1 mol/L) GBCA at 0.1 mmol/kg bodyweight provides no appreciable clinical advantage relative to published findings for conventional GBCAs at standard concentration (0.5 mol/L) when compared with gadobenate dimeglumine at an identical dose of 0.1 mmol/kg bodyweight. The lack of any appreciable benefit with gadobutrol can be ascribed to the fact that the SI during the interstitial phase (i.e. at post-injection acquisition times of 3-10 minutes as typically performed for brain tumor imaging) depends solely on the total amount of gadolinium in the lesion (i.e., the total number of gadolinium molecules) and its relaxivity rather than on the gadolinium solution concentration. Secondly, it is clear that higher r1 relaxivity is instrumental in improving diagnostic performance relative to that achievable with conventional GBCAs at equivalent dose.”

These conclusions support a literature review and simulation model, published last year, which concluded that most clinical trials to date have not found a benefit for higher concentration MRI agents. Instead, it is the dose and relaxivity of a compound, not the concentration, which significantly influence signal intensity in MRI.

Statistically significant (p<0.0001; all readers, all comparisons) results in favor of MultiHance were demonstrated for each individual diagnostic information endpoint used in the study, as well as for quantitative parameters linked to the contrast enhancement obtained with the two agents (contrast-to-noise ratio, [CNR] and lesion to brain ratio [LBR]), when a preference was expressed by the three independent blinded readers.

“The key importance of this study is that its results were similar to prior clinical investigations of this kind comparing Magnevist (gadopentetate dimeglumine) to MultiHance, and Omniscan (gadodiamide) to MultiHance, so you now have three studies of this design demonstrating similar findings for contrast agents used for MRI,” said Alberto Spinazzi, senior vice president of worldwide medical and regulatory affairs at Bracco Diagnostics Inc. “These results are consistent in showing some clear advantages relative to performance associated with using the highest relaxivity agent for CNS MRI, MultiHance, versus other GBCAs.”

The two contrast injections were performed in a blinded and fully randomized manner with an interval of two to fourteen days between administrations, to avoid any carryover effects. Half of the patients received MultiHance for their first exam and the other half received Gadavist first. Imaging parameters and post-dose acquisition times were kept identical for the two exams of each patient. To maintain the study blind, each agent was administered by an independent drug-dispensing person. Images were evaluated by three independent and experienced neuroradiologists, who were unaffiliated with the enrollment centers, and fully blinded to any clinical information about the patients and the agents used in the two exams. Image assessments were made in terms of diagnostic information (global diagnostic preference, lesion border delineation, definition of disease extent, visualization of lesion internal morphology, lesion contrast enhancement) and quantitative parameters (signal intensity [SI], CNR and LBR).

The findings of all 3 readers in global diagnostic preference were highly significant (p<0.0001) between the 2 agents. Readers 1, 2 and 3 reported global preference for MultiHance in 40.7, 47.4, and 43 percent of patients compared with 5.3, 6.1 and 6.1 percent of patients for Gadavist, respectively. Similar highly significant preference was demonstrated for each individual diagnostic endpoint. Reader preference was based on superior contrast enhancement and better delineation of lesion and/or internal lesion structure.

“Bracco Diagnostics believes that MultiHance may improve the visualization of CNS disorders in MRI, and that relaxivity, not concentration, is what matters when it comes to improved image quality, noted Carlo Medici, president and CEO of Bracco Diagnostics Inc. “We are pleased that this large-scale clinical investigation supported this. This concurrence of clinical evidence is an important criterion for clinicians when making evidence-based decisions.”

For more information: www.multihanceusa.com

Related Content

AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire)

AIR Recon DL delivers shorter scans and better image quality (Photo: Business Wire).

News | Artificial Intelligence | May 29, 2020
May 29, 2020 — GE Healthcare announced U.S.
United Imaging's uMR OMEGA is designed to provide greater access to magnetic resonance imaging (MRI) with the world’s first ultra-wide 75-cm bore 3T MRI.
News | Magnetic Resonance Imaging (MRI) | May 27, 2020
May 27, 2020 — United Imaging's...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue

A new technique developed by researchers at UC Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. Image courtesy of Xiandoing Xue, UC Davis

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers at the University of California, Davis offers a...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Remote reading of imaging studies on home picture archiving and communication systems (PACS) workstations can contribute to social distancing, protect vulnerable radiologists and others in the hospital, and ensure seamless interpretation capabilities in emergency scenarios, according to an open-access article published ahead-of-print by the American Journal of Roentgenology (AJR).

Srini Tridandapani, M.D., Ph.D.

News | PACS | May 21, 2020
May 21, 2020 — 
Examples of chest CT images of COVID-19 (+) patients and visualization of features correlated to COVID-19 positivity. For each pair of images, the left image is a CT image showing the segmented lung used as input for the CNN (convolutional neural network algorithm) model trained on CT images only, and the right image shows the heatmap of pixels that the CNN model classified as having SARS-CoV-2 infection (red indicates higher probability). (a) A 51-year-old female with fever and history of exposure to SARS-

Figure 1: Examples of chest CT images of COVID-19 (+) patients and visualization of features correlated to COVID-19 positivity. For each pair of images, the left image is a CT image showing the segmented lung used as input for the CNN (convolutional neural network algorithm) model trained on CT images only, and the right image shows the heatmap of pixels that the CNN model classified as having SARS-CoV-2 infection (red indicates higher probability). (a) A 51-year-old female with fever and history of exposure to SARS-CoV-2. The CNN model identified abnormal features in the right lower lobe (white color), whereas the two radiologists labeled this CT as negative. (b) A 52-year-old female who had a history of exposure to SARS-CoV-2 and presented with fever and productive cough. Bilateral peripheral ground-glass opacities (arrows) were labeled by the radiologists, and the CNN model predicted positivity based on features in matching areas. (c) A 72-year-old female with exposure history to the animal market in Wuhan presented with fever and productive cough. The segmented CT image shows ground-glass opacity in the anterior aspect of the right lung (arrow), whereas the CNN model labeled this CT as negative. (d) A 59-year-old female with cough and exposure history. The segmented CT image shows no evidence of pneumonia, and the CNN model also labeled this CT as negative.  

News | Coronavirus (COVID-19) | May 19, 2020
May 19, 2020 — Mount Sinai researchers are the first in the country to use...
Advanced imaging data exchange is now live in Colorado due to the partnership of Health Images and the Colorado Regional Health Information Organization

Getty Images

News | Radiology Business | May 18, 2020
May 18, 2020 — 
Now a research team — led by Tohoku University Professor, Wataru Yashiro — has developed a new method using intense synchrotron radiation that produces higher quality images within milliseconds.

How the bent crystal changes the direction of the X-rays. Image courtesy of Tohoku University

News | Computed Tomography (CT) | May 15, 2020
May 15, 2020 — Many will undergo a computed tomogr...